BMO Capital Maintains Outperform on Eli Lilly, Raises Price Target to $633
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Evan Seigerman has maintained an Outperform rating on Eli Lilly (NYSE:LLY) and raised the price target from $565 to $633.
August 09, 2023 | 2:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's price target has been raised from $565 to $633 by BMO Capital, maintaining an Outperform rating.
The raised price target and maintained Outperform rating by BMO Capital indicates a positive outlook for Eli Lilly. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100